Denali Therapeutics price target lowered to $32 from $35 at BTIG
BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...
Palo Alto Networks shares fall as Deutsche Bank, BTIG downgrade rating
Shares of Palo Alto Networks (NASDAQ:PANW) fell more than 2% in premarket trading Wednesday after analysts at BTIG and Deutsche Bank (ETR:DBKGn) downgraded the stock.
BTIG Sticks to Their Buy Rating for Stryker (SYK)
BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker (SYK – Research Report) yesterday and set a price target of $394.00. The ...
VYNE Therapeutics (VYNE) Gets a Buy from BTIG
In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report), with a price ...
Fintel on MSN14h
BTIG Initiates Coverage of Hims & Hers Health (HIMS) with Buy Recommendation
Fintel reports that on January 7, 2025, BTIG initiated coverage of Hims & Hers Health (NYSE:HIMS) with a Buy recommendation.